Aldeyra Therapeutics has enrolled the first patient in a Phase III INVIGORATE clinical trial being conducted to assess reproxalap for the treatment of allergic conjunctivitis.

Reproxalap is a small molecule covalent inhibitor of reactive aldehyde species (RASP), which are known to be higher in ocular and systemic inflammatory diseases. RASP cause the activation of intracellular inflammatory factors, including NF-kB, inflammasomes and Scavenger Receptor A.

Reproxalap demonstrated statistically significant and clinically relevant activity in late-phase clinical conditions, according to the company.

A 0.25% dose of the immune-modulating drug led to a statistically significant decrease in ocular itching and redness in a Phase II allergen chamber clinical methods study, compared to the vehicle.

The randomised, double-masked, crossover vehicle-controlled INVIGORATE trial is designed to compare the safety and efficacy of the 0.25% reproxalap ophthalmic solution to a vehicle using an allergen chamber.

The study, which is set to enrol a total of 120 participants, will track subject-reported ocular itching score as the primary endpoint. Secondary outcomes include conjunctival redness assessed by the subject.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is expected to be completed in September.

Aldeyra Therapeutics president and CEO Todd Brady said: “Standard of care antihistamines are ineffective in nearly a quarter of all allergic conjunctivitis patients, many of whom require adjunct therapy, including corticosteroids, which cannot be used chronically due to toxicity.

“We believe that reproxalap may offer a durable and highly differentiated approach for the treatment of ocular allergy, a condition that is increasing in prevalence but has not benefited from the introduction of a novel therapeutic approach in decades.”

Last month, Aldeyra commenced enrolment in the Phase III GUARD clinical trial of ADX-2191 being developed to prevent a rare retinal disease called proliferative vitreoretinopathy.